• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.

作者信息

Damy Thibaud, Sultan Marla B, Witteles Ronald

机构信息

French Referral Center for Cardiac Amyloidosis, Amyloidosis Mondor Network, GRC Amyloid Research Institute and Department of Cardiology, all at APHP, CHU Henri Mondor; and INSERM U955, Clinical Investigation Center 006, and DHU ATVB, all at Créteil, Créteil, France.

Pfizer Inc, New York, NY, USA.

出版信息

Eur J Heart Fail. 2021 Jun;23(6):1057-1058. doi: 10.1002/ejhf.2074. Epub 2021 Feb 16.

DOI:10.1002/ejhf.2074
PMID:33340199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8359258/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecf/8359258/8250f2fe26de/EJHF-23-1057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecf/8359258/8250f2fe26de/EJHF-23-1057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecf/8359258/8250f2fe26de/EJHF-23-1057-g001.jpg

相似文献

1
Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.关于文章《转甲状腺素蛋白心肌病临床试验（ATTR-ACT）中他法米地斯剂量的疗效和安全性及长期扩展研究》信件的回复
Eur J Heart Fail. 2021 Jun;23(6):1057-1058. doi: 10.1002/ejhf.2074. Epub 2021 Feb 16.
2
Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.关于文章《转甲状腺素蛋白心肌病临床试验（ATTR-ACT）中他法米地斯剂量的疗效与安全性及长期扩展研究》的信函
Eur J Heart Fail. 2021 Apr;23(4):681-682. doi: 10.1002/ejhf.2049. Epub 2020 Nov 12.
3
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.在转甲状腺素蛋白心肌病临床试验（ATTR-ACT）和长期扩展研究中，他司美替尼剂量的疗效和安全性。
Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12.
4
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.他法米替尼在遗传性和野生型转甲状腺素蛋白淀粉样心肌病患者中的疗效：来自ATTR-ACT 的进一步分析。
JACC Heart Fail. 2021 Feb;9(2):115-123. doi: 10.1016/j.jchf.2020.09.011. Epub 2020 Dec 9.
5
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).转甲状腺素蛋白淀粉样心肌病患者心血管住院和死亡的原因（来自转甲状腺素蛋白心肌病临床试验 [ATTR-ACT]中的塔法米迪司）。
Am J Cardiol. 2021 Jun 1;148:146-150. doi: 10.1016/j.amjcard.2021.02.035. Epub 2021 Mar 3.
6
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.用塔法米迪治疗转甲状腺素蛋白淀粉样心肌病患者的长期生存。
Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20.
7
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.在 3 期ATTR-ACT 研究和正在进行的长期扩展研究中，塔法米迪在 80 岁以上患者中的疗效。
JACC Heart Fail. 2024 Jan;12(1):150-160. doi: 10.1016/j.jchf.2023.08.032. Epub 2023 Nov 8.
8
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.服用他法米地斯的转甲状腺素蛋白淀粉样心肌病患者的长期生存：通俗易懂的总结
Future Cardiol. 2023 Jan;19(1):7-17. doi: 10.2217/fca-2022-0096. Epub 2023 Jan 30.
9
Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark. Letter regarding the article 'Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms'.他法米地对心力衰竭住院治疗的影响：未吠之犬的故事。关于文章《他法米地治疗转甲状腺素蛋白淀粉样心肌病和严重心力衰竭症状患者可改善长期生存率》的信函
Eur J Heart Fail. 2024 Feb;26(2):526. doi: 10.1002/ejhf.3015. Epub 2023 Sep 6.
10
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.塔法米迪在转甲状腺素蛋白淀粉样变心肌病患者中的健康影响：来自转甲状腺素蛋白心肌病临床试验（ATTR-ACT）和开放标签长期扩展研究的分析。
Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):529-538. doi: 10.1093/ehjqcco/qcab031.

引用本文的文献

1
Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.他司美替尼：甲状腺素运载蛋白淀粉样心肌病治疗药物。
Am J Cardiovasc Drugs. 2021 Jan;21(1):113-121. doi: 10.1007/s40256-020-00461-7. Epub 2021 Jan 20.

本文引用的文献

1
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.在转甲状腺素蛋白心肌病临床试验（ATTR-ACT）和长期扩展研究中，他司美替尼剂量的疗效和安全性。
Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12.
2
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.